Troponin I (hs-TnI) is a key cardiac biomarker used for the prompt identification and diagnosis of myocardial injury. Troponin I, a protein involved in regulating cardiac muscle contraction, is released into the bloodstream when heart muscle cells are damaged.
Clinical Significance of High-Sensitivity Troponin I lies in its role in diagnosing and managing diseases, including:
- Elevated hs-TnI is associated with a worse prognosis in chronic heart failure, chronic kidney disease, and diabetes.
- May indicate ongoing subclinical myocardial injury.
- May help rule out myocardial infarction in chest pain of non-cardiac origin.
- Elevated hs-TnI may be observed in sepsis, pulmonary embolism, stroke, and COVID-19.
Different Diagnostic ways to test for hs–Troponin–I levels
Commonly used methods to detect hs-Troponin-I levels in laboratories include electrochemiluminescence (ECLIA), Chemiluminescence Immunoassay (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), and fluorescence-based immunoassay methods (FIA). The detection of hs-Troponin-I, based on a Chemiluminescence Immunoassay, is used for quantitative measurement of hs-Troponin-I levels in human serum/plasma as an aid in the diagnosis of Myocardial Infarction.
Conclusion Highly Sensitive Troponin I is a valuable cardiac biomarker for accurately detecting myocardial injury, including minor myocardial damage. Increased hs-TnI levels are commonly detected in more severe cases and are closely linked to higher rates of complications, including myocarditis, arrhythmias, heart failure, and overall mortality. Its high sensitivity is useful for early risk assessment and treatment planning.
Explore the Product…
